Berglund, Alysia M.
Raugh, Ian M.
Macdonald, Kelsey I.
James, Sydney H.
Bartolomeo, Lisa A.
Knippenberg, Anna R.
Strauss, Gregory P.
Funding for this research was provided by:
National Institute of Mental Health (R21-MH112925, R21-MH122863, R01-MH116039)
Article History
Received: 10 August 2022
Accepted: 9 January 2023
First Online: 21 January 2023
Declarations
:
: GS is one of the original developers of the Brief Negative Symptom Scale (BNSS) and receives royalties and consultation fees from ProPhase LLC in connection with commercial use of the BNSS and other professional activities; these fees are donated to the Brain and Behavior Research Foundation. GS has received honoraria and travel support from ProPhase LLC for training pharmaceutical company raters on the BNSS. In the past three years, GS has consulted for and/or been on the speaker bureau for Minerva Neurosciences, Boehringer Ingelheim, Acadia, Otsuka, Sunovion, and Lundbeck pharmaceutical companies. All other authors have no conflicts to report.
Free to read: This content has been made available to all.